Overexpression of CD166 in papillary thyroid carcinoma (PTC) was independently associated with a shorter progression-free survival, higher nodal and tumor stages suggesting that CD166 may be a potential therapeutic target to treat PTC [28]. This evidence concerns the gene ALCAM and differentiated thyroid carcinoma.